

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 February 2023 (23.02.2023)



(10) International Publication Number
WO 2023/021008 A1

(51) International Patent Classification:
A61K 31/519 (2006.01) *A61P 25/18* (2006.01)
A61P 3/06 (2006.01)

(21) International Application Number:
PCT/EP2022/072793

(22) International Filing Date:
15 August 2022 (15.08.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/235,331 20 August 2021 (20.08.2021) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: GOPAL, Srihari; 173 Berkley Avenue, Belle
Mead, New Jersey 08502 (US). MILZ, Ruth; 1125
Trenton-Harbourton Road, Titusville, New Jersey 08560
(US). WANG, Steven; 1125 Trenton-Harbourton Road, Ti-

tusville, New Jersey 08560 (US). NAJARIAN, Dean; 1771
West Street, Wrentham, Massachusetts 02093 (US). SAN-
GA, Panna; 1125 Trenton-Harbourton Road, Titusville,
New Jersey 08560 (US). LOUIE, John; 510 Cottonwood
Drive, Milpitas, California 95035 (US).

(74) Agent: WARNER, James Alexander et al.; Carpmals
& Ransford LLP, One Southampton Row, London WC1B
5HA (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: DOSING REGIMENS ASSOCIATED WITH EXTENDED RELEASE PALIPERIDONE INJECTABLE FORMU-
LATIONS




FIG. 1

(57) Abstract: The present invention provides methods of treating patients with long acting injectable paliperidone palmitate formula-
tions. The disclosure includes methods for mitigating at least one adverse change in blood lipid levels of a patient in need thereof who
has been treated with a paliperidone palmitate extended-release injectable suspension at either one-month intervals (PP1M) or three-
month intervals (PP3M), comprising transitioning the patient to a paliperidone palmitate extended-release injectable suspension having
a six month dosing interval (PP6M).

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))